BlackRock Discloses Passive Stake in Harrow, Inc. Common Stock
Ticker: HROW · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals
TL;DR
**BlackRock just revealed a big, passive stake in Harrow, Inc., signaling institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Harrow, Inc. (formerly Harrow Health Inc.), a pharmaceutical preparations company. This filing indicates BlackRock's passive ownership of Harrow's Common Stock, signaling their belief in the company's long-term prospects without seeking to influence management. For investors, this means a large, reputable institution sees value in Harrow, potentially adding a layer of stability and institutional confidence to the stock.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant, passive stake in Harrow, Inc., which can be a vote of confidence for current and prospective shareholders.
Risk Assessment
Risk Level: low — The filing indicates a passive investment by a large institution, which generally reduces risk by adding stability and institutional backing.
Analyst Insight
A smart investor would view BlackRock's passive stake as a positive signal, potentially indicating long-term value, and might consider further research into Harrow, Inc.'s fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — the investment firm filing the SC 13G
- HARROW, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its passive stake in Harrow, Inc. for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
- Harrow, Inc.'s stock may experience increased investor confidence due to BlackRock's reported stake. (HARROW, INC.) — medium confidence, target: March 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically designated under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the subject company of this filing?
The subject company is HARROW, INC., which was formerly known as HARROW HEALTH INC. and Imprimis Pharmaceuticals, Inc.
Who is the entity making this filing?
The entity making this filing is BlackRock Inc., a major investment management corporation.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of HARROW, INC. is 415858109.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding HARROW, INC. (HROW).